{"id":"nccn-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"NCCN chemotherapy protocols are evidence-based treatment guidelines that combine chemotherapeutic drugs with complementary mechanisms of action to maximize tumor cell kill while managing toxicity. These regimens are tailored to specific cancer types and stages, often including agents that target DNA synthesis, microtubule stability, or other critical cellular processes. The specific drugs and dosing vary by indication and patient factors.","oneSentence":"NCCN Chemotherapy refers to a standardized chemotherapy regimen recommended by the National Comprehensive Cancer Network, typically combining multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:40.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors and hematologic malignancies (indication-specific per NCCN guidelines)"}]},"trialDetails":[{"nctId":"NCT07462728","phase":"NA","title":"Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guizhou Medical University","startDate":"2026-03-30","conditions":"Non Small Cell Lung Cancer Metastatic, Radiotherapy","enrollment":200},{"nctId":"NCT04763356","phase":"NA","title":"Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2023-01-10","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":422},{"nctId":"NCT04302025","phase":"PHASE2","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT06290687","phase":"PHASE2","title":"Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-02-18","conditions":"Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT07413146","phase":"NA","title":"Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Minimal Residual Disease, Immunoscore, Neoadjuvant Chemotherapy","enrollment":100},{"nctId":"NCT05488626","phase":"NA","title":"Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer","status":"WITHDRAWN","sponsor":"Varian, a Siemens Healthineers Company","startDate":"2022-10-20","conditions":"Stage III Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT07369882","phase":"NA","title":"Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-12","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT07349043","phase":"PHASE1","title":"A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01","conditions":"Peritoneal Metastasis, CRC (Colorectal Cancer)","enrollment":42},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04908696","phase":"","title":"Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-12-01","conditions":"Glottic Carcinoma, Supraglottic Carcinoma, Subglottic Carcinoma","enrollment":1000},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT03694756","phase":"NA","title":"TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2018-12-12","conditions":"Breast Cancer","enrollment":95},{"nctId":"NCT06446115","phase":"NA","title":"Decreasing Chemotherapy Induced Distress Using Immersive Virtual Reality in Patients With Cancer","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-11-05","conditions":"Malignant Neoplasm, Cancer","enrollment":70},{"nctId":"NCT05456685","phase":"PHASE2","title":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-09-28","conditions":"High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer","enrollment":125},{"nctId":"NCT07167446","phase":"EARLY_PHASE1","title":"Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2025-10-14","conditions":"Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy","enrollment":30},{"nctId":"NCT07050563","phase":"NA","title":"Clinical Evaluation of the Tiaoshen Anti-Cancer Regimen in Treating Psycho-Neurological Symptom Cluster in Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2025-10-06","conditions":"Cancer, Cancer Symptom Clusters","enrollment":316},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT07153952","phase":"PHASE1, PHASE2","title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-01","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Radiotherapy","enrollment":60},{"nctId":"NCT06249321","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Pancreatic Cancer, Radiotherapy","enrollment":30},{"nctId":"NCT06149689","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-10","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT06582342","phase":"","title":"Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2024-03-21","conditions":"Adenocarcinoma of the Pancreas","enrollment":70},{"nctId":"NCT04467593","phase":"NA","title":"Safety Study of Whole Body Hyperthermia for Advanced Cancer","status":"COMPLETED","sponsor":"ElmediX","startDate":"2021-07-28","conditions":"Advanced Cancer, Pancreatic Cancer Metastatic","enrollment":16},{"nctId":"NCT07014202","phase":"PHASE2","title":"Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-11","conditions":"Non-Small Cell Lung Cancer","enrollment":224},{"nctId":"NCT06990737","phase":"PHASE2","title":"Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-06-25","conditions":"Cutaneous Squamous Cell Carcinoma of the Head and Neck, Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck","enrollment":24},{"nctId":"NCT06320717","phase":"","title":"AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-01-02","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":100},{"nctId":"NCT06864533","phase":"NA","title":"Adjuvant Chemotherapy for High Malignant Prostate Cancer","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2019-09-01","conditions":"Prostate Cancer, Radiation Therapy, Chemotherapy","enrollment":315},{"nctId":"NCT06914674","phase":"PHASE2","title":"Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-20","conditions":"Pancreatic Neoplasms","enrollment":30},{"nctId":"NCT04091867","phase":"PHASE1","title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":3},{"nctId":"NCT06436157","phase":"NA","title":"A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2024-12-26","conditions":"Solid Tumor, Adult","enrollment":60},{"nctId":"NCT05780372","phase":"PHASE3","title":"Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-08-08","conditions":"Nasopharyngeal Carcinoma, Radiotherapy; Complications","enrollment":474},{"nctId":"NCT06775652","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC","status":"COMPLETED","sponsor":"Yongtao Han","startDate":"2018-01-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":254},{"nctId":"NCT06766578","phase":"PHASE2","title":"Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2024-12-31","conditions":"Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":32},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT03515538","phase":"PHASE2","title":"Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2018-07-12","conditions":"Oral Mucositis","enrollment":53},{"nctId":"NCT04723875","phase":"PHASE3","title":"Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2021-01-28","conditions":"Uterine Cervical Neoplasms, Cervical Cancer","enrollment":306},{"nctId":"NCT04450706","phase":"NA","title":"Functional Precision Oncology for Metastatic Breast Cancer","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-02-16","conditions":"HER2-negative Breast Cancer","enrollment":15},{"nctId":"NCT03901339","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-08","conditions":"Metastatic Breast Cancer","enrollment":543},{"nctId":"NCT05462496","phase":"PHASE2","title":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-03-16","conditions":"Pancreatic Cancer","enrollment":25},{"nctId":"NCT06435104","phase":"PHASE2","title":"Aromatherapy in the Treatment of Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07","conditions":"Early Breast Cancer","enrollment":30},{"nctId":"NCT06339060","phase":"PHASE3","title":"An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Esophageal Cancer","enrollment":356},{"nctId":"NCT06019130","phase":"PHASE2","title":"Nivolumab in Children and Adults With Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2023-01-10","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms","enrollment":57},{"nctId":"NCT06391892","phase":"PHASE3","title":"Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","status":"RECRUITING","sponsor":"Elisabethinen Hospital","startDate":"2024-01-11","conditions":"Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model","enrollment":100},{"nctId":"NCT06366945","phase":"PHASE2","title":"Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-20","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC","enrollment":85},{"nctId":"NCT06306846","phase":"PHASE2","title":"Neoadjuvant SBRT in Localized Advanced HNSCC","status":"RECRUITING","sponsor":"Jiang Feng","startDate":"2023-10-01","conditions":"Head and Neck Squamous Carcinoma","enrollment":81},{"nctId":"NCT06196554","phase":"","title":"Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs","status":"UNKNOWN","sponsor":"Dong Bing Zhao","startDate":"2023-05-01","conditions":"Gastric Cancer, Organoid, Neoadjuvant Therapy","enrollment":40},{"nctId":"NCT04379739","phase":"PHASE2","title":"Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-07-26","conditions":"Non Small Cell Lung Cancer","enrollment":89},{"nctId":"NCT06154109","phase":"PHASE2","title":"Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhiyu Wang","startDate":"2023-11-25","conditions":"Triple Negative Breast Neoplasms","enrollment":90},{"nctId":"NCT05307198","phase":"PHASE2","title":"Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-11","conditions":"Rectal Neoplasms","enrollment":38},{"nctId":"NCT05569811","phase":"PHASE2","title":"NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-11-25","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT04728724","phase":"PHASE2","title":"Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-09-10","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":100},{"nctId":"NCT05681390","phase":"PHASE2","title":"Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-01-01","conditions":"Pancreatic Neoplasms","enrollment":30},{"nctId":"NCT05888129","phase":"","title":"Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2017-01-01","conditions":"Postoperative Complications","enrollment":1},{"nctId":"NCT05863377","phase":"","title":"Efficacy of Chemotherapy Alone in Patients With Poor-differentiated Early-stage Cervical Cancer","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-01-01","conditions":"Cervical Cancer","enrollment":450},{"nctId":"NCT04667793","phase":"PHASE2","title":"Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-01-31","conditions":"Thymic Epithelial Tumor","enrollment":15},{"nctId":"NCT02582008","phase":"EARLY_PHASE1","title":"Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-01","conditions":"Current Smoker, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":9},{"nctId":"NCT05720559","phase":"PHASE2","title":"Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-01","conditions":"Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer","enrollment":100},{"nctId":"NCT05673343","phase":"","title":"The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-01-04","conditions":"the Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatment","enrollment":100},{"nctId":"NCT05627960","phase":"PHASE1","title":"First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies","status":"RECRUITING","sponsor":"A&G Pharmaceutical Inc.","startDate":"2022-02-14","conditions":"Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer","enrollment":77},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT03099265","phase":"PHASE2","title":"Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-06-26","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT04248595","phase":"PHASE2","title":"Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML","status":"UNKNOWN","sponsor":"Ge Zheng","startDate":"2019-12-01","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT01265849","phase":"PHASE3","title":"Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity","status":"COMPLETED","sponsor":"CEL-SCI Corporation","startDate":"2010-12","conditions":"Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate","enrollment":928},{"nctId":"NCT04931394","phase":"PHASE3","title":"Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2021-06-01","conditions":"Pancreatic Cancer","enrollment":200},{"nctId":"NCT04931381","phase":"PHASE3","title":"Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2021-06-01","conditions":"Advanced Pancreatic Cancer","enrollment":100},{"nctId":"NCT05438342","phase":"NA","title":"An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-11-01","conditions":"Advanced Cancer, Metastatic Cancer","enrollment":195},{"nctId":"NCT05280210","phase":"NA","title":"PTC in Personalizing Neoadjuvant Therapy for Patients With Advanced Gastrointestinal Tumor","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-04-01","conditions":"Gastrointestinal Neoplasms","enrollment":420},{"nctId":"NCT02551263","phase":"","title":"Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2015-07-22","conditions":"Breast Cancer","enrollment":201},{"nctId":"NCT04737551","phase":"","title":"Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-01-01","conditions":"Resectable Pancreatic Cancer, Adjuvant Chemoradiotherapy, Surgery","enrollment":400},{"nctId":"NCT04733820","phase":"PHASE3","title":"Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2021-02-01","conditions":"Uterine Cervical Neoplasms, Cervical Cancer","enrollment":340},{"nctId":"NCT04677192","phase":"PHASE2","title":"Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01","conditions":"Pancreatic Cancer Metastatic to Liver, Oligometastasis","enrollment":50},{"nctId":"NCT04370925","phase":"PHASE3","title":"Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2020-06-04","conditions":"Colorectal Cancer","enrollment":688},{"nctId":"NCT01112826","phase":"PHASE3","title":"Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2010-04-23","conditions":"Breast Cancer","enrollment":443},{"nctId":"NCT04264468","phase":"","title":"Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-05-14","conditions":"Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer","enrollment":150},{"nctId":"NCT03620955","phase":"","title":"Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-08-10","conditions":"Risk-directed Therapy, Cytogenetic Abnormality, Molecular Abnormality","enrollment":1000},{"nctId":"NCT03023436","phase":"PHASE3","title":"Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-01","conditions":"Stomach Neoplasm","enrollment":220},{"nctId":"NCT02338752","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Pancreatic Neoplasms","enrollment":20},{"nctId":"NCT02127268","phase":"PHASE3","title":"Thymosin-α1 in Cancer-Related Fatigue","status":"UNKNOWN","sponsor":"Zhigang Zhang","startDate":"2014-04","conditions":"Cancer Related Fatigue, Quality of Life","enrollment":200},{"nctId":"NCT02786524","phase":"NA","title":"Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2016-02-15","conditions":"Uterine Cervical Neoplasms, Ovarian Neoplasms, Gynecologic Neoplasms","enrollment":107},{"nctId":"NCT03777930","phase":"PHASE4","title":"The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol","status":"UNKNOWN","sponsor":"Shenzhen Fifth People's Hospital","startDate":"2018-12-10","conditions":"Cancer, Therapy-Related","enrollment":200},{"nctId":"NCT03733834","phase":"","title":"SD vs. NSD Therapy in Elderly AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-10-08","conditions":"Standard Therapy, Non-standard Therapy","enrollment":1000},{"nctId":"NCT03142282","phase":"PHASE2","title":"Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-01-01","conditions":"Metastatic Colorectal Cancer, Radiotherapy","enrollment":200},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT01796444","phase":"PHASE3","title":"Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node","status":"WITHDRAWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2013-01","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT03455205","phase":"NA","title":"Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2017-12-24","conditions":"Digestive Tract","enrollment":270},{"nctId":"NCT03412994","phase":"PHASE2","title":"Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Liqiang Zhong","startDate":"2018-02-28","conditions":"Colorectal Neoplasms","enrollment":60},{"nctId":"NCT02659345","phase":"NA","title":"Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-05","conditions":"Cancer","enrollment":50},{"nctId":"NCT02215837","phase":"PHASE2","title":"Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2014-08","conditions":"Gastric Cancer, Neoplasms, Gastrointestinal Neoplasms","enrollment":40},{"nctId":"NCT02651441","phase":"PHASE1, PHASE2","title":"D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2016-02","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT01503905","phase":"NA","title":"Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2011-12","conditions":"Breast Cancer Nos Premenopausal","enrollment":600},{"nctId":"NCT02772107","phase":"PHASE2, PHASE3","title":"Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-12","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":132},{"nctId":"NCT02766348","phase":"PHASE2","title":"Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2016-05","conditions":"NSCLC","enrollment":60},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT01900951","phase":"PHASE2","title":"Temozolomide as Maintenance Therapy in Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2013-01","conditions":"Carcinoma, Small Cell","enrollment":60},{"nctId":"NCT02202928","phase":"PHASE2","title":"Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2014-07","conditions":"Colorectal Cancer, Neoplasms, Intestinal Neoplasms","enrollment":60},{"nctId":"NCT02338804","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Breast Neoplasms","enrollment":20},{"nctId":"NCT02333474","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Lung Neoplasms","enrollment":20},{"nctId":"NCT02338778","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Liver Neoplasms","enrollment":20},{"nctId":"NCT02338700","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Prostatic Neoplasms","enrollment":20},{"nctId":"NCT01839539","phase":"PHASE2","title":"Study of DC-CIK to Treat Colorectal Cancer","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2013-03","conditions":"Colorectal Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":929,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Chemotherapy strategy for controlled group"],"phase":"phase_3","status":"active","brandName":"NCCN Chemotherapy","genericName":"NCCN Chemotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NCCN Chemotherapy refers to a standardized chemotherapy regimen recommended by the National Comprehensive Cancer Network, typically combining multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis. Used for Various solid tumors and hematologic malignancies (indication-specific per NCCN guidelines).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}